Detailed explanation of the efficacy and clinical feedback of cosibelimab-UNLOXCYT

Cosibelimab (UNLOXCYT) as a programmed death ligand-1 (PD-L1 ) blocking antibody effectively activates the immune system to attack cancer cells by blocking the binding of PD-L1 and PD-1. The drug is specifically indicated for the treatment of adult patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced cutaneous squamous cell carcinoma (laCSCC), especially those who are unable to undergo curative surgery or radical radiotherapy. In December 2024, cosibelimab was approved by the U.S. Food and Drug Administration (FDA) for official marketing, providing an important new option for the treatment of cutaneous squamous cell carcinoma.

According toCK-301-101 study data, cosibelimab has demonstrated significant clinical efficacy in the treatment of cutaneous squamous cell carcinoma. For patients with metastatic disease, the objective response rate (ORR) reached 47% (95%) in 78 patients CI, 36%-59%), meaning that nearly half of patients had a significant response to treatment. Among 31 patients with locally advanced cutaneous squamous cell carcinoma, the objective response rate was also as high as 48% (95% CI, 30%-67%), which is equivalent to the efficacy in patients with metastatic disease.

In terms of duration of response, the median duration of response (DOR) in patients with metastatic disease was 17.7 months (range: 3.7 months to 17.7+ months), The median duration of response in patients with locally advanced disease also reached 1.4 months (range: 1.4 months to 34.1 months). These data fully demonstrate that cosibelimab can achieve long-term disease control in some patients.

Cosibelimab has shown a high objective response rate in patients with metastatic and locally advanced cutaneous squamous cell carcinoma, providing patients with a new treatment option, and some patients have a longer median response duration, effectively delaying the progression of the disease and significantly improving the patient's quality of life. It is particularly worth mentioning that this drug is particularly suitable for patients who are not suitable for radical surgery or radiotherapy, filling the treatment gap for these patients.

However, the use of cosibelimab may also be associated with a series of adverse reactions. Common side effects include fatigue, rash, diarrhea, hypothyroidism, etc., while serious immune-related adverse reactions may include pneumonia, hepatitis, etc. Therefore, patients must undergo treatment under the guidance of a doctor and regularly monitor their physical condition to ensure the safety and effectiveness of the treatment.

https://ir.checkpointtx.com/news-events/press-releases/detail/127/checkpoint-therapeutics-announces-fda-approval-of